Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 98,948 |
|
|||||
| News | - | ||||||
| Day High | 13.115 | Low High |
|||||
| Day Low | 12.61 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lexeo Therapeutics Inc | LXEO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.31 | 2.49% | 12.77 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.82 | 12.61 | 13.115 | 12.77 | 12.46 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,876 | 98,948 | US$ 12.84 | US$ 1,270,371 | - | 9.00 - 22.33 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:04:37 | formt | 1,877 | US$ 12.77 | USD |
Lexeo Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 339.5M | 26.67M | - | 0 | -66.39M | -2.49 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lexeo Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXEO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.14 | 13.33 | 11.985 | 12.43 | 188,334 | 0.63 | 5.19% |
| 1 Month | 13.11 | 15.06 | 11.57 | 12.49 | 115,369 | -0.34 | -2.59% |
| 3 Months | 17.18 | 17.38 | 11.57 | 14.36 | 118,129 | -4.41 | -25.67% |
| 6 Months | 9.50 | 22.33 | 9.00 | 13.75 | 120,973 | 3.27 | 34.42% |
| 1 Year | 9.50 | 22.33 | 9.00 | 13.75 | 120,973 | 3.27 | 34.42% |
| 3 Years | 9.50 | 22.33 | 9.00 | 13.75 | 120,973 | 3.27 | 34.42% |
| 5 Years | 9.50 | 22.33 | 9.00 | 13.75 | 120,973 | 3.27 | 34.42% |
Lexeo Therapeutics Description
| Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. |
